Table 1 Demographic and Baseline Characteristics
Molecular analysis set N = 159 | Safety analysis set N = 170 | |
|---|---|---|
Age | ||
Mean (SD) | 59.9 (11.9) | 59.7 (12.0) |
Median (Q1-Q3) | 60.0 (51.0–69.0) | 60.0 (51.0–69.0) |
BMI (Kg/m2) | ||
Mean (SD) | 25.2 (4.9) | 25.5 (4.9) |
Median (Q1-Q3) | 24.5 (21.8–28.4) | 24.7 (22.0–28.5) |
Time from diagnosis (years) | ||
Mean (SD) | 7.8 (5.8) | 7.9 (5.8) |
Median (Q1-Q3) | 6.0 (3.4–11.0) | 6.1 (3.5–11.0) |
Histology—n (%) | ||
Ductal | 120 (85.7) | 129 (86.6) |
Lobular | 20 (14.3) | 20 (13.4) |
Unknown/missing | 19 (11.9) | 21 (12.3) |
Biological subtype—n (%) | ||
HER2 positive | 27 (18.8) | 28 (18.3) |
Luminal | 91 (63.2) | 99 (64.7) |
Triple Negative | 26 (18.1) | 26 (17.0) |
Missing | 15 (9.4) | 17 (10) |
Metastasis—n (%) | ||
Not visceral | 50 (31.4) | 53 (31.2) |
Visceral | 109 (68.6) | 117 (68.8) |
Number of therapy lines in metastatic setting—n (%) | ||
Mean (SD) | 5.0 (3.1) | 5.0 (3.0) |
Median (Q1-Q3) | 5.0 (3.0–7.0) | 5.0 (3.0–7.0) |
Missing | 3 (1.9) | 3 (1.7) |
Baseline neurotoxicity—n (%) | ||
No | 132 (83.0) | 143 (84.1) |
Yes | 27 (17.0) | 27 (15.9) |